Cellebrite Names Dr. Guy Rotkopf as Chairperson of Ethics & Integrity Committee
Former Director General of the Israel Ministry of Justice to oversee Committee activities
PETAH TIKVA, Israel and TYSONS CORNER, Va., March 08, 2022 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that Dr. Guy Rotkopf, former Director General of the Israel Ministry of Justice, has been named as the new Chairperson of Cellebrite’s Ethics & Integrity Committee. Dr. Rotkopf brings to the Committee a strong law and academic background. Dr. Rotkopf has a PH. D. in law from Bar-Ilan University, an LL. M from Duke University School of Law, and an LL. B in law from the Academic College of Management.
Founded in August of 2021, the Committee advises the Board of Directors on matters pertaining to evolving international law, ethical considerations related to responsible business practices, and requirements under law and regulations applied to the sale and use of Cellebrite’s technologies. Rotkopf will oversee a committee currently comprised of eight members with diverse backgrounds in human rights, education, foreign affairs, defense, national security, and technology use in the public and in the private sector.
Cellebrite CEO, Yossi Carmil, said, “We welcome the addition of Dr. Rotkopf to the Ethics and Integrity Committee. His skillset and experience will complement the backgrounds of the existing committee members and provide us with added perspective to ensure Cellebrite receives expert recommendations and consultancy on implementing best practices in ethics as part of our ongoing business practices.”
“It’s with great integrity that I accept this appointment and I will, together with the members of the Ethics and Integrity Committee, work hard to provide guidance towards ethical practices that support the principles and policies guiding Cellebrite’s sales of solutions and services, stance on emerging and developing trends, and adapting policies to address ethics and human rights matters,” said Dr. Guy Rotkopf.
Cellebrite’s mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the globe. The Ethics & Integrity Committee will further this mission by providing the Board with unbiased, expert advice to ensure adherence to high ethical standards for the benefit of all stakeholders.
For more information about Cellebrite’s commitment to Ethics and Integrity, please visit:
https://cellebrite.com/en/ethics-integrity.
About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.
Caution Regarding Forward Looking Statements
This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the business of Cellebrite are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to develop technologically advanced solutions and successfully integrate with the software solutions used by customers; acceptance of solutions by customers; errors, failures, defects or bugs in solutions; a failure to maintain sales and marketing personnel productivity or hire, integrate and retain additional sales and marketing personnel; the impact of the global COVID-19 pandemic; the impact of competition on pricing and on Cellebrite’s market share; sub-optimal results from products due to misuse by customers; Cellebrite’s failure to maintain and enhance its reputation and brand; inaccuracy of the estimates of Cellebrite’s market opportunity and forecasts of market growth; changes to packaging and licensing models that adversely affect the ability to attract or retain customers; failure to manage future growth effectively; failure to introduce new solutions and add-ons; issues in the use of artificial intelligence resulting in reputational harm or liability; the need for additional capital to support the growth of Cellebrite’s business; a failure to maintain the security of operations and the integrity of software solutions; the impact of government budgeting cycles and appropriations, early termination, audits, investigations, sanctions and penalties; a decline in government budgets, changes in spending or budgetary priorities, or delays in contract awards; a failure to adequately obtain, maintain, protect and enforce Cellebrite’s intellectual property or infringement of the intellectual property rights of others; perceptions or court or regulatory decisions that Cellebrite’s solutions violate privacy rights; the use of solutions by customers in a way that is, or that is perceived to be, incompatible with human rights; failure to comply with laws regarding privacy, data protection and security, technology protection, sanctions, export controls and other matters; and other factors, risks and uncertainties set forth in the sections titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the final proxy statement/prospectus filed with the SEC on August 5, 2021 and in other documents filed by Cellebrite with the SEC, which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
Contacts
Media
Adam Jaffe
VP of Global Communications
+1 973 206 7643
adam.jaffe@cellebrite.com
- or -
RapidResponse@cellebrite.com
Investors
Anat Earon-Heilborn
VP Investor Relations
+972 73 394 8440
investors@cellebrite.com
